ALLIANCES AND COLLABORATIONS (Otsuka) (Details) (USD $)	3 Months Ended								12 Months Ended											12 Months Ended													12 Months Ended				12 Months Ended				12 Months Ended				12 Months Ended		12 Months Ended		12 Months Ended		12 Months Ended		12 Months Ended		12 Months Ended
	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2010	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2011 ABILIFY [Member]	Dec. 31, 2010 ABILIFY [Member]	Dec. 31, 2009 ABILIFY [Member]	Dec. 31, 2011 Otsuka [Member] ABILIFY [Member]	Dec. 31, 2010 Otsuka [Member] ABILIFY [Member]	Dec. 31, 2009 Otsuka [Member] ABILIFY [Member]	Dec. 31, 2011 Otsuka [Member] ABILIFY [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 1999 Otsuka [Member] ABILIFY [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2011 Otsuka [Member] ABILIFY, SPRYCEL and IXEMPRA [Member]	Dec. 31, 2010 Otsuka [Member] ABILIFY, SPRYCEL and IXEMPRA [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] ABILIFY [Member]	Dec. 31, 2012 Otsuka [Member] United States [Member] ABILIFY [Member]	Dec. 31, 2011 Otsuka [Member] United States [Member] ABILIFY [Member]	Dec. 31, 2010 Otsuka [Member] United States [Member] ABILIFY [Member]	Dec. 31, 2009 Otsuka [Member] United States [Member] ABILIFY [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] ABILIFY [Member] Annual net sales up to 2 Point 7 billion [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] ABILIFY [Member] Annual net sales between 2 Point 7 billion and 3 Point 2 billion [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] ABILIFY [Member] Annual net sales between 3 Point 2 billion and 3 Point 7 billion [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] ABILIFY [Member] Annual net sales between 3 Point 7 billion and 4 Point 0 billion [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] ABILIFY [Member] Annual net sales between 4 Point 0 billion and 4 Point 2 billion [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] ABILIFY [Member] Annual net sales over 4 Point 2 billion [Member]	Dec. 31, 2011 Otsuka [Member] United States [Member] ABILIFY [Member] Extension payment [Member]	Dec. 31, 2010 Otsuka [Member] United States [Member] ABILIFY [Member] Extension payment [Member]	Dec. 31, 2009 Otsuka [Member] United States [Member] ABILIFY [Member] Extension payment [Member]	Apr. 30, 2009 Otsuka [Member] United States [Member] ABILIFY [Member] Extension payment [Member]	Dec. 31, 2011 Otsuka [Member] United States [Member] ABILIFY [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2010 Otsuka [Member] United States [Member] ABILIFY [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2009 Otsuka [Member] United States [Member] ABILIFY [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2011 Otsuka [Member] France, Germany, Spain, and United Kingdom [Member] ABILIFY [Member]	Dec. 31, 2011 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member]	Dec. 31, 2010 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member]	Dec. 31, 2011 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Operating expense up to $175 million [Member]	Dec. 31, 2011 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Operating expenses over $175 million [Member]	Dec. 31, 2011 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Annual net sales up to $400 million [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Annual net sales up to $400 million [Member]	Dec. 31, 2011 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Annual net sales between $400 and $600 million [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Annual net sales between $400 and $600 million [Member]	Dec. 31, 2011 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Annual net sales between $600 and $800 million [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Annual net sales between $600 and $800 million [Member]	Dec. 31, 2011 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Annual net sales between $800 million and $1 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Annual net sales between $800 million and $1 billion [Member]	Dec. 31, 2011 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Annual net sales over $1 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Annual net sales over $1 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Annual net sales up to 2 Point 7 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Annual net sales between 2 Point 7 billion and 3 Point 2 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Annual net sales between 3 Point 2 billion and 3 Point 7 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Annual net sales between 3 Point 7 billion and 4 Point 0 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Annual net sales between 4 Point 0 billion and 4 Point 2 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] SPRYCEL and IXEMPRA [Member] Annual net sales over 4 Point 2 billion [Member]
Alliances and Collaborations Statement [Line Items]
Percentage of net sales recognized from collaboration																							51.50%	53.50%	58.00%	65.00%	50.00%	20.00%	7.00%	2.00%	1.00%	20.00%								65.00%
Percentage of operating expense reimbursements from collaboration																						50.00%		30.00%																			20.00%	1.00%
Payment to extend term of commercialization agreement																																				$ 400,000,000
Total upfront, milestone and other licensing payments																		60,000,000
Percentage of net sales payable to collaboration partner																								1.50%																					30.00%	65.00%	5.00%	12.00%	3.00%	3.00%	2.00%	2.00%	1.00%	1.00%
Range of sales at which a given percentage will be paid to collaboration partner - maximum																																													400,000,000		600,000,000		800,000,000		1,000,000,000				2,700,000,000	3,200,000,000	3,700,000,000	4,000,000,000	4,200,000,000
Range of sales at which a given percentage will be paid to collaboration partner - minimum																																															400,000,000		600,000,000		800,000,000		1,000,000,000			2,700,000,000	3,200,000,000	3,700,000,000	4,000,000,000	4,200,000,000
Amount of operating expense at or below which collaboration partner will reimburse given percentage																																											175,000,000
Amount of operating expense over which collaboration partner will reimburse given percentage																																												175,000,000
ABILIFY* net sales, including amortization of extension payment	5,454,000,000	5,345,000,000	5,434,000,000	5,011,000,000	5,111,000,000	4,798,000,000	4,768,000,000	4,807,000,000	21,244,000,000	19,484,000,000	18,808,000,000	2,758,000,000	2,565,000,000	2,592,000,000	2,758,000,000	2,565,000,000	2,592,000,000
Oncology Products collaboration fee expense																																									134,000,000	128,000,000
Royalty expense															72,000,000	62,000,000	58,000,000
Reimbursement of operating expenses to/(from) Otsuka																				(88,000,000)	(101,000,000)
Amortization (income)/expense - extension payment																																	66,000,000	66,000,000	49,000,000
Amortization expense - upfront, milestone and other licensing payments									(271,000,000)	(199,000,000)	(170,000,000)																										6,000,000	6,000,000	6,000,000
Other assets - extension payment	824,000,000				1,005,000,000				824,000,000	1,005,000,000																							219,000,000	285,000,000
Other intangible assets - upfront, milestone and other licensing payments	3,124,000,000				3,370,000,000				3,124,000,000	3,370,000,000																											5,000,000	11,000,000
Total upfront, milestone and other licensing payments expensed to IPRD																			157,000,000
Total capitalized and expensed upfront, milestone and other licensing payments																		$ 217,000,000